TCI Wealth Advisors Inc. Sells 7,601 Shares of The Clorox Company (NYSE:CLX)

TCI Wealth Advisors Inc. decreased its holdings in shares of The Clorox Company (NYSE:CLX - Free Report) by 35.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,554 shares of the company's stock after selling 7,601 shares during the period. TCI Wealth Advisors Inc.'s holdings in Clorox were worth $2,208,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Semanteon Capital Management LP raised its position in shares of Clorox by 3.5% during the third quarter. Semanteon Capital Management LP now owns 6,298 shares of the company's stock worth $1,026,000 after purchasing an additional 213 shares during the period. Insight Folios Inc raised its holdings in Clorox by 3.0% during the 3rd quarter. Insight Folios Inc now owns 2,195 shares of the company's stock worth $358,000 after buying an additional 63 shares during the period. Frank Rimerman Advisors LLC acquired a new stake in Clorox during the 3rd quarter worth about $206,000. Boston Trust Walden Corp boosted its holdings in shares of Clorox by 5,442.5% in the third quarter. Boston Trust Walden Corp now owns 273,908 shares of the company's stock worth $44,622,000 after buying an additional 268,966 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Clorox by 3.3% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 45,777 shares of the company's stock worth $7,458,000 after buying an additional 1,465 shares during the period. Institutional investors and hedge funds own 78.53% of the company's stock.

Clorox Stock Performance

Shares of NYSE:CLX traded up $1.03 during trading on Monday, reaching $157.72. The stock had a trading volume of 1,062,657 shares, compared to its average volume of 1,222,443. The stock has a fifty day simple moving average of $160.74 and a two-hundred day simple moving average of $145.63. The company has a quick ratio of 0.63, a current ratio of 1.03 and a debt-to-equity ratio of 5.04. The Clorox Company has a 52 week low of $114.68 and a 52 week high of $169.09. The firm has a market capitalization of $19.59 billion, a price-to-earnings ratio of 81.19, a P/E/G ratio of 3.19 and a beta of 0.41.

Clorox (NYSE:CLX - Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported $1.82 EPS for the quarter, topping the consensus estimate of $1.54 by $0.28. Clorox had a net margin of 3.95% and a return on equity of 281.12%. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.97 billion. As a group, analysts anticipate that The Clorox Company will post 6.64 earnings per share for the current fiscal year.

Clorox Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, November 7th. Investors of record on Wednesday, October 23rd will be paid a dividend of $1.22 per share. This represents a $4.88 annualized dividend and a yield of 3.09%. The ex-dividend date is Wednesday, October 23rd. Clorox's payout ratio is currently 252.85%.

Insider Buying and Selling at Clorox

In other Clorox news, EVP Angela C. Hilt sold 1,733 shares of the firm's stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $165.52, for a total value of $286,846.16. Following the completion of the sale, the executive vice president now owns 13,471 shares in the company, valued at approximately $2,229,719.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.51% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on CLX shares. TD Cowen initiated coverage on shares of Clorox in a research note on Tuesday, July 23rd. They issued a "sell" rating and a $122.00 price objective for the company. Jefferies Financial Group raised Clorox from a "hold" rating to a "buy" rating and upped their price target for the company from $174.00 to $187.00 in a research report on Tuesday, October 1st. Barclays raised their price objective on Clorox from $130.00 to $137.00 and gave the stock an "underweight" rating in a research report on Friday, October 11th. Citigroup increased their price target on shares of Clorox from $165.00 to $170.00 and gave the stock a "neutral" rating in a research report on Friday, September 6th. Finally, Evercore ISI lowered their price objective on shares of Clorox from $140.00 to $139.00 and set an "underperform" rating on the stock in a research report on Monday, October 14th. Six equities research analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Clorox presently has a consensus rating of "Hold" and a consensus price target of $150.14.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.